| Age at admission in years [n=22 (100.0%)] | ||
| Mean (SD) | 47.59 | (20.55) |
| Median (IQR) | 47.25 | (37.80,62.10) |
| Sex, n (%) [n=22 (100.0%)] | ||
| Female | 3 | (13.6%) |
| Male | 19 | (86.4%) |
| Pregnancy status, n (% of females) [n=2 (66.7%)] | ||
| Not known to be pregnant | 2 | (100.0%) |
| Recently pregnant | 0 | ( 0.0%) |
| Currently pregnant | 0 | ( 0.0%) |
| Body mass index categories, n (%) [n=22 (100.0%)] | ||
| <18.5 | 10 | (45.5%) |
| 18.5-<25 | 8 | (36.4%) |
| 25-<30 | 3 | (13.6%) |
| 30-<40 | 1 | ( 4.5%) |
| 40+ | 0 | ( 0.0%) |
| Dependency prior to admission, n (%) [n=22 (100.0%)] | ||
| Able to live without assistance in daily activities | 9 | (40.9%) |
| Minor assistance with some daily activities | 13 | (59.1%) |
| Major assistance with majority of or all daily activities | 0 | ( 0.0%) |
| Total assistance with all daily activities | 0 | ( 0.0%) |
| HIV, n (%) [n=16 (72.7%)] | ||
| No HIV | 10 | (62.5%) |
| ART compliant | 5 | (31.2%) |
| ART non-compliant | 0 | ( 0.0%) |
| Not on ART | 1 | ( 6.2%) |
| TB, n (%) [n=22 (100.0%)] | ||
| No TB | 21 | (95.5%) |
| TB | 1 | ( 4.5%) |
| Hyptertension, n (%) [n=20 (90.9%)] | ||
| No severe hypertension | 20 | (100.0%) |
| Hypertension | 0 | ( 0.0%) |
| Congestive cardiac failure, n (%) [n=22 (100.0%)] | ||
| No congestive cardiac failure | 22 | (100.0%) |
| Congestive cardiac failure | 0 | ( 0.0%) |
| Stroke, n (%) [n=22 (100.0%)] | ||
| No stroke | 22 | (100.0%) |
| Stroke | 0 | ( 0.0%) |
| Diabetes, n (%) [n=22 (100.0%)] | ||
| No diabetes | 22 | (100.0%) |
| On insulin | 0 | ( 0.0%) |
| On tablets | 0 | ( 0.0%) |
| Not on treatment | 0 | ( 0.0%) |
| NEWS2 score [n=22 (100.0%)] | |||
| Median (IQR) | 6.5 | (5.25,9.75) | (5.25,9.75) |
| UVA score [n=16 (72.7%)] | |||
| Median (IQR) | 2.5 | (1,5) | (1,5) |
| PF ratio [n=22 (100.0%)] | |||
| Mean (SD) | 31.03 | (13.23) | (13.23) |
| Median (IQR) | 23.39 | (20.62,44.41) | (20.62,44.41) |
| [0,13.3) | 0 | ( 0.0%) | (0.0%) |
| [13.3,26.7) | 12 | (54.5%) | (54.5%) |
| [26.7,Inf) | 10 | (45.5%) | (45.5%) |
| Outcome at the end of critical care, n (%) [n=22 (100.0%)] | ||
| Discharged | 13 | (59.1%) |
| Died | 6 | (27.3%) |
| Absconded | 0 | ( 0.0%) |
| Unknown | 3 | (13.6%) |
| Length of stay [n=20 (90.9%)] | ||
| Mean (SD) | 4.05 | (2.61) |
| Median (IQR) | 3.50 | (2.00,6.00) |
| Length of stay (critical care survivors; N=13) [n=13 (100.0%)] | ||
| Mean (SD) | 3.46 | (2.67) |
| Median (IQR) | 3.00 | (2.00,4.00) |
| Length of stay (critical care non survivors; N=6) [n=6 (100.0%)] | ||
| Mean (SD) | 5.17 | (2.48) |
| Median (IQR) | 5.50 | (3.50,6.00) |
| Organ support (at any time during critical care stay), n (%) [n=22 (100.0%)] | ||
| Oxygen | 20 | (90.9%) |
| Fluid balance | 10 | (45.5%) |
| Neurological observation | 5 | (22.7%) |
| Intravenous drug (not vasoactive) | 2 | ( 9.1%) |
| Intravenous drug (vasoactive) | 0 | ( 0.0%) |
| Continuous monitoring | 20 | (90.9%) |
| Intubation & ventilation | 2 | ( 9.1%) |
| Other | 9 | (40.9%) |
| Duration of oxygen support (days) [n=20 (100.0%)] | ||
| Mean (SD) | 2.85 | (2.11) |
| Median (IQR) | 2.00 | (1.00,3.25) |
| Duration of fluid balance (days) [n=10 (100.0%)] | ||
| Mean (SD) | 3.10 | (2.38) |
| Median (IQR) | 2.00 | (1.00,5.75) |
| Duration of neurological observation (days) [n=5 (100.0%)] | ||
| Mean (SD) | 1.40 | (0.55) |
| Median (IQR) | 1.00 | (1.00,2.00) |
| Duration of intravenous drug administration (not vasoactive) (days) [n=2 (100.0%)] | ||
| Mean (SD) | 1.00 | (0.00) |
| Median (IQR) | 1.00 | (1.00,1.00) |
| Duration of intravenous drug administration (vasoactive) (days) [n=0 (NaN%)] | ||
| Mean (SD) | NaN | (-) |
| Median (IQR) | – | (-,-) |
| Duration of continuous monitoring (days) [n=20 (100.0%)] | ||
| Mean (SD) | 2.70 | (2.30) |
| Median (IQR) | 1.50 | (1.00,3.25) |
| Duration of intubation & ventilation (days) [n=2 (100.0%)] | ||
| Mean (SD) | 1.00 | (0.00) |
| Median (IQR) | 1.00 | (1.00,1.00) |
| Duration of other organ support (days) [n=9 (100.0%)] | ||
| Mean (SD) | 2.11 | (1.05) |
| Median (IQR) | 2.00 | (1.00,3.00) |
| Age [n=22 (100.0%)] | ||||||||||
| 0-29 | 0 | (0.0%) | 0 | (0.0%) | 1 | (50.0%) | 0 | (0.0%) | 0 | (0.0%) |
| 30-39 | 0 | (0.0%) | 0 | (0.0%) | 1 | (16.7%) | 0 | (0.0%) | 0 | (0.0%) |
| 40-49 | 0 | (0.0%) | 0 | (0.0%) | 0 | ( 0.0%) | 0 | (0.0%) | 0 | (0.0%) |
| 50-59 | 0 | (0.0%) | 0 | (0.0%) | 2 | (66.7%) | 0 | (0.0%) | 0 | (0.0%) |
| 60+ | 0 | (0.0%) | 0 | (0.0%) | 2 | (28.6%) | 0 | (0.0%) | 0 | (0.0%) |
| Sex [n=22 (100.0%)] | ||||||||||
| Female | 0 | (0.0%) | 0 | (0.0%) | 0 | ( 0.0%) | 0 | (0.0%) | 0 | (0.0%) |
| Male | 0 | (0.0%) | 0 | (0.0%) | 6 | (31.6%) | 0 | (0.0%) | 0 | (0.0%) |
| BMI [n=22 (100.0%)] | ||||||||||
| <18.5 | 0 | (0.0%) | 0 | (0.0%) | 2 | (20.0%) | 0 | (0.0%) | 0 | (0.0%) |
| 18.5-<25 | 0 | (0.0%) | 0 | (0.0%) | 2 | (25.0%) | 0 | (0.0%) | 0 | (0.0%) |
| 25-<30 | 0 | (0.0%) | 0 | (0.0%) | 2 | (66.7%) | 0 | (0.0%) | 0 | (0.0%) |
| 30-<40 | 0 | (0.0%) | 0 | (0.0%) | 0 | ( 0.0%) | 0 | (0.0%) | 0 | (0.0%) |
| 40+ | 0 | (NaN%) | 0 | (NaN%) | 0 | ( NaN%) | 0 | (NaN%) | 0 | (NaN%) |
| HIV status [n=16 (72.7%)] | ||||||||||
| No HIV | 0 | (0.0%) | 0 | (0.0%) | 2 | ( 20.0%) | 0 | (0.0%) | 0 | (0.0%) |
| ART compliant | 0 | (0.0%) | 0 | (0.0%) | 1 | ( 20.0%) | 0 | (0.0%) | 0 | (0.0%) |
| ART non-compliant | 0 | (NaN%) | 0 | (NaN%) | 0 | ( NaN%) | 0 | (NaN%) | 0 | (NaN%) |
| Not on ART | 0 | (0.0%) | 0 | (0.0%) | 1 | (100.0%) | 0 | (0.0%) | 0 | (0.0%) |
| TB status [n=22 (100.0%)] | ||||||||||
| No TB | 0 | (0.0%) | 0 | (0.0%) | 5 | ( 23.8%) | 0 | (0.0%) | 0 | (0.0%) |
| TB | 0 | (0.0%) | 0 | (0.0%) | 1 | (100.0%) | 0 | (0.0%) | 0 | (0.0%) |
| NEWS2 score [n=22 (100.0%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 9.83 | (2.14) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 10.50 | ( 9.25,11.00) | – | (-,-) | – | (-,-) |
| UVA score [n=16 (72.7%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 3.50 | (1.91) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 4.00 | (2.50,5.00) | – | (-,-) | – | (-,-) |
| Length of stay (days) [n=20 (90.9%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 5.17 | (2.48) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 5.50 | (3.50,6.00) | – | (-,-) | – | (-,-) |
| Organ support (at any time during critical care) [n=22 (100.0%)] | ||||||||||
| Oxygen | 0 | (0.0%) | 0 | (0.0%) | 6 | (30.0%) | 0 | (0.0%) | 0 | (0.0%) |
| Fluid balance | 0 | (0.0%) | 0 | (0.0%) | 4 | (40.0%) | 0 | (0.0%) | 0 | (0.0%) |
| Neurological observation | 0 | (0.0%) | 0 | (0.0%) | 3 | (60.0%) | 0 | (0.0%) | 0 | (0.0%) |
| Intravenous drug (not vasoactive) | 0 | (0.0%) | 0 | (0.0%) | 1 | (50.0%) | 0 | (0.0%) | 0 | (0.0%) |
| Intravenous drug (vasoactive) | 0 | (NaN%) | 0 | (NaN%) | 0 | ( NaN%) | 0 | (NaN%) | 0 | (NaN%) |
| Continuous monitoring | 0 | (0.0%) | 0 | (0.0%) | 6 | (30.0%) | 0 | (0.0%) | 0 | (0.0%) |
| Intubation & ventilation | 0 | (0.0%) | 0 | (0.0%) | 1 | (50.0%) | 0 | (0.0%) | 0 | (0.0%) |
| Other | 0 | (0.0%) | 0 | (0.0%) | 2 | (22.2%) | 0 | (0.0%) | 0 | (0.0%) |
| Duration of oxygen support (days) [n=20 (100.0%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 4.00 | (2.45) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 3.00 | (2.25,5.25) | – | (-,-) | – | (-,-) |
| Duration of fluid balance (days) [n=10 (100.0%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 4.00 | (2.45) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 4.50 | (2.50,6.00) | – | (-,-) | – | (-,-) |
| Duration of neurological observation (days) [n=5 (100.0%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 1.67 | (0.58) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 2.00 | (1.50,2.00) | – | (-,-) | – | (-,-) |
| Duration of intravenous drug administration (not vasoactive) (days) [n=2 (100.0%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 1.00 | (-) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 1.00 | (1.00,1.00) | – | (-,-) | – | (-,-) |
| Duration of intravenous drug administration (vasoactive) (days) [n=0 (NaN%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | – | (-) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | – | (-,-) | – | (-,-) | – | (-,-) |
| Duration of continuous monitoring (days) [n=20 (100.0%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 4.00 | (2.45) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 3.00 | (2.25,5.25) | – | (-,-) | – | (-,-) |
| Duration of intubation & ventilation (days) [n=2 (100.0%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 1.00 | (-) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 1.00 | (1.00,1.00) | – | (-,-) | – | (-,-) |
| Duration of other organ support (days) [n=9 (100.0%)] | ||||||||||
| Mean (SD) | – | (-) | – | (-) | 2.50 | (0.71) | – | (-) | – | (-) |
| Median (IQR) | – | (-,-) | – | (-,-) | 2.50 | (2.25,2.75) | – | (-,-) | – | (-,-) |